What is SEED?
SEED stands for the Study to Explore Early
Development. It is a 5-year, multi-site collaborative study that
will help identify what might put children at risk for autism
spectrum disorders (ASDs) and other developmental disabilities. It
is being conducted by six study sites and a data coordinating center
called the Centers for Autism and Developmental Disabilities
Research and Epidemiology (CADDRE) Network.
What are the six CADDRE centers?
The six CADDRE centers are:
- California CADDRE: Kaiser Permanente Division of Research
and the California Department of Health Services
- Colorado CADDRE: Colorado Department of Public Health and
Environment and the University of Colorado at Denver and Heath
Sciences Center
- Georgia CADDRE: the National Center on Birth Defects and
Developmental Disabilities
- Maryland CADDRE: Johns Hopkins University and Kennedy
Krieger Institute
- North Carolina CADDRE: University of North Carolina at
Chapel Hill
- Pennsylvania CADDRE: University of Pennsylvania School of
Nursing and The Children’s Hospital of Pennsylvania
Where exactly is SEED being conducted?
California
a two county area: Alameda and Santa Clara counties
Colorado
the seven-county Denver metropolitan area:
(Arapahoe, Adams, Boulder, Broomfield, Denver, Douglas, and
Jefferson counties).
Georgia (CDC)
the five-county metropolitan Atlanta area: Clayton,
Cobb, DeKalb, Fulton, and Gwinnett counties.
Maryland
seven jurisdictions in northeastern Maryland: Anne
Arundel, Baltimore, Carroll, Cecil, Harford and Howard Counties and
Baltimore City.
North Carolina
a ten county area: Alamance, Chatham, Davidson,
Durham, Forsyth, Guilford, Johnston, Orange, Randolph, and Wake
counties.
Pennsylvania
three counties: Chester, Montgomery and Philadelphia
counties.
*CDC also funds Michigan State University to run the
study’s Data Coordinating Center and Johns Hopkins University to run
the study's central laboratory.
How were the sites selected?
The sites were originally picked through an open
competitive review process in 2001 and funded for 5 years. The sites
were selected based on the merit of their application. In 2006, CDC
had a limited competitive review process and funded the sites for
another 5 years.
How can I enroll my child into the study?
The study is a population based study – meaning that
the participants will be recruited from all children and families in
each study community who meet certain criteria rather then focusing
on individuals at a specific clinic or school. Families of children
with specific developmental conditions, as well as a random sample
of all children born in the community will be invited to
participate. If the invited family is interested, then we ask some
questions to determine if they are eligible, and if they are
eligible then the family is enrolled.
Can I sign my child up for this study?
Although families can self-refer to participate in
this study, they have to fulfill certain criteria in order to be
eligible. Some families who self refer may not be eligible. Our goal
is to send letters of invitation to all families who may fulfill the
eligibility criteria. By sending letters of invitation to as many
eligible families as possible, we hope to enroll a representative
sample of families in each study area.
Examples of the study eligibility criteria include -
the child must be born within the study period, the child must be
born and still living in the study area, they must have a legal
guardian, they must know English or Spanish (although these vary by
site), and they must also meet certain diagnostic criteria.
What will each study participant have to do?
Each parent or caregiver will have to answer
questions about their child’s development and their family’s medical
history. The study clinicians will perform a brief exam and
developmental tests on the child. Each parent and child will have to
give small samples of blood, cells from inside the mouth, and a
sample of the child’s hair. Finally, we would access the mother’s
and the child’s medical records.
Why are we only looking at children in 6 states?
The funding for the study allowed us to support 6
study sites around the country.
Why are we only looking at children between the ages
of 2-5?
The study will focus on children who are 2 to 5
years old. This age range was selected to reduce the amount of time
since pregnancy and early development so that parent recall of
events during these time periods is better, so that medical
information is easier to retrieve, so that families are less likely
to have moved away from the study area, and it will also be nearer
the beginning of treatment for children in developmental
intervention programs.
We selected these research factors after an
extensive review of the literature. We designated each of the
factors as high priority based on the how strongly they seemed to be
associated with ASD and what new information we needed to collect
about each factor, balanced by how well we could study each factor
with our particular study methods.
Will the study include vaccines as a potential cause
of autism?
Yes, the study will include vaccines. The mercury
exposures being studies include – vaccines that the mom received
during pregnancy, the child's vaccine exposures after birth and
specific other factors such as RhoGAM treatment in pregnancy if the
mom has developed an immune response against the fetus that can harm
it.
There are several studies, including studies funded
by the government, now looking at environmental exposures in autism
such as mercury. SEED doesn’t want to duplicate the work of these
other studies, but since we are getting medical records, we choose
to look at information on vaccines and other types of medical
procedures that may have mercury exposure that we can get through
medical records.
Will CDC find out if thimerosal causes autism?
It is too soon to speculate on the results of the
study. We hope the study will give us a better idea of which of the
risk factors that we will be looking at seem to be the most
important in causing autism.
If the study shows that thimerosal is a cause of
autism, will CDC report the data? What guarantees does the public
have that the findings won’t be covered up?
We will report all the findings of the study by
following the normal scientific review process as soon as possible.
When the study is completed, will we know the causes
of autism?
It is too soon to speculate on the results of the
study. We hope the study will give us a better idea of which of the
risk factors that we will be looking at seem to be the most
important in causing autism. The causes may be related to genes, the
environment, or a relationship between the two – such as if some
groups of children with certain genes are more easily harmed by some
environmental exposures.
Will this study find a prevention/cure for autism?
It is too soon to speculate on what we might find
about the causes of autism. But, we are hopeful that the findings
from SEED will help the development of future studies specifically
designed to assess treatments among children with autism.
What are the other developmental disabilities being
studied?
We will be studying a range of other developmental
disabilities, including mental retardation, developmental delay, and
other behavioral problems in early childhood.
Why are we looking at other developmental
disabilities?
By comparing children with autism and children with
other developmental disabilities we will try to see if the risk
factors we observe in children with autism are unique to autism or
if they are also important in children with other developmental
problems.
Looking at children with other developmental
disabilities will also provide a way of comparing responses of
children with developmental disabilities, in general, versus
typically developing children.
How will you get the names of children to invite
into the study?
We are working with our partners in the community
who serve children with developmental problems and through these
partners we will be sending out letters to families to invite them
to participate.
Why didn't or doesn't the 2001/2002 funding
represent "the first national study"?
In the initial grant awards (2001/2002), the
grantees were responsible for 3 activities: setting up monitoring
programs for autism and other developmental disorders, collaboration
on the multi-site epidemiologic study, and investigator-initiated
special studies. Although the multi-site study was planned, funding
levels were not adequate to implement the multi-site study during
the 2002/2002 funding cycle. Consequently, implementation was
delayed until the current funding cycle. All funds awarded to the
grantees in the current grant cycle are dedicated to implementation
of the multi-site study. The grantees competed for funding to
continue their monitoring activities under a separate grant
announcement earlier in 2006, and no funding will be available for
investigator-initiated special studies.
In what way(s) will the sample populations be
representative of all children?
It seems that by not including major states like New
York, Illinois, Texas, etc. it's hard to claim this is "nationally
representative"? Further, how will the selection/recruitment
processes ensure or foster generalizability?
The two groups of children with ASD and other
developmental problems will be identified in multiple clinical and
educational facilities in each community to insure that the
participants are representative of all children with these types of
developmental problems - and not just children who might be seen at
a single clinic or intervention program. The third group of study
children will be randomly selected from all children born in each
community during the same time period so that they are
representative of all children in the study area most of whom do not
have developmental problems.
Although resources do not permit the sample to be
drawn so that it is statistically representative of all children in
the nation, by conducting the study in 6 different geographic areas
across the country with diverse populations and by identifying
children from multiple sources in each community we hope to have a
study sample that more closely represents children with ASD, other
developmental problems, and typical development across the country.
Will there be interim results or will the study
first have results six or so years from now?
Many of the core study hypotheses will require that
we have data collection completed on the full study sample before
analysis can take be completed, but some interim analyses that
require less than the full study sample may be possible. We don’t
want to rush interim analyses, however, before we have a good
representative sample of children.
What do you mean by "community diversity"?
SEED is located in select study areas within 6
states: 2 counties in the San Francisco, California area, 7 counties
in the Denver, Colorado area, 5 counties in the Atlanta, Georgia
area, 7 counties in the Baltimore and northeast Maryland area, 10
counties in central North Carolina, and 3 counties in the
Philadelphia, Pennsylvania area.
These study areas include diverse communities and
populations from which study participants will be drawn.
Can this really be classified as a national study
since it only involves six states?
It is a multi-site study set in diverse communities
in 6 locations around the country: California, Colorado, Georgia,
Maryland, North Carolina, and Pennsylvania.
Although resources do not permit the sample to be
drawn so that it is statistically representative of all children in
the nation, by conducting the study in 6 different geographic areas
across the country with diverse populations and by identifying
children from multiple sources in each community we hope to have a
study sample that more closely represents children with ASD, other
developmental problems, and typical development across the country.
How will this give us national insight?
Compared to a study located in a single area, our
study in six different areas gives us geographic and community
diversity that will give us greater insights into the variability of
who is at risk and what are the risk factors for autism.
What is the methodology for collecting the data?
Same for each state?
Yes, all the sites are using a common study protocol
– meaning they are following the same procedures for recruiting
participants and collecting data so that, at the end, the data from
all 6 sites can be pooled into a single large data base for
analysis.
We will be asking participants to complete
self-administered questionnaires; interviewing mothers about
pregnancy-related issues and developmental conditions in their
children; conducting a developmental exam of each study child to
evaluate cognitive and
emotional development, language and adaptive skills,
and motor skills, and a dysmorphology exam of the child (that will
look at physical features that may indicate an underlying genetic
condition); taking cheek swab and blood samples from the mother;
father, and child; taking a hair sample from the child; and looking
at the mother and child’s medical records.
Do all 2,700 of the children have an ASD?
No, there will be 900 children in each of 3 groups:
children with ASDs, children with other developmental problems, and
children drawn from the community most of whom are typically
developing.
I live in one of the states with a CADDRE center.
Who can I contact for more information about the study?
California CADDRE
Kaiser Permanente Division of Research
California Department of Health Services
Oakland, CA
510.620.3700
Colorado CADDRE
Colorado Department of Public Health and Environment
University of Colorado at Denver and Heath Sciences Center
Denver, CO
303.315.0066
303.692.2680
Georgia CADDRE
National Center on Birth Defects and Developmental Disabilities
Atlanta, GA
404.498.0058
Maryland CADDRE
Johns Hopkins University
Kennedy Krieger Institute
Baltimore, MD
877.868.8014
North Carolina CADDRE
University of North Carolina at Chapel Hill
Chapel Hill, NC
919.966.2068
Pennsylvania CADDRE
University of Pennsylvania School of Nursing
The Children’s Hospital of Pennsylvania
Philadelphia, PA
215.573.2469
215.590.7474
Date:
May 28, 2008
Content source: National Center on Birth Defects and Developmental
Disabilities